# Genomics Core

> **NIH NIH P50** · CORIELL INSTITUTE FOR MEDICAL RESEARCH · 2024 · $238,562

## Abstract

Abstract - Genomics, Epigenomics and Bioinformatics Core
The Genomics, Epigenomics, and Bioinformatics Core will provide personnel, equipment, and expertise to
support all projects of the Epigenetic Therapy SPORE. The Core will be a resource for design and execution of
genomic and epigenomic experiments, data acquisition, quality control, bioinformatic analysis, data
management, sharing and distribution. It will closely cooperate with all SPORE Projects and the
Pathology/Biospecimen Core. Project 1 studies immune-sensitization by inhibition of cyclin-dependent kinase
CDK9. It will discover whether clinically targetable CDKs are also epigenetic regulators and conduct pre-clinical
and clinical studies of combined epigenetic therapy and immunotherapy using CDK inhibitors, DNA
methyltransferase (DNMT) inhibitors and immune checkpoint inhibitors. The Core will analyze (i) gene
expression and chromatin accessibility in tumor and immune cells in preclinical models of tumors treated with
CDK9 inhibitors, (ii) genome-wide effects of CDK4, 6 and 7 inhibition on DNA methylation and gene
expression, and (iii) support preclinical studies and a clinical trial combining CDK9, DNMT and immune
checkpoints inhibitors by the analysis of collected samples for transcriptomic and epigenetic parameters (gene
expression and expression of endogenous retroviruses and repetitive elements by RNA-seq, DNA methylation
by RRBS) and immune cell parameters (gene expression and markers of exhaustion in sorted T cells). The
Core will also perform whole exome sequencing (WES) to determine whether baseline DNA mutation and DNA
methylation profiles predict response. Project 2 is focused on epigenetic synergy between inhibitors of DNMT
and Polycomb repressive complex subunits EZH1/2 for therapy in solid tumors. The Core will analyze and
integrate DNA methylation, ChIP-seq, RNA-seq and WES data to assess the combinatory effects of DNMT and
EZH1/2 inhibitors and perform single-cell RNA-seq analysis of the tumor tissue to delineate tumor-associated
immune populations. Project 3 combines induction of inflammasome signaling by hypomethylating agents with
inhibitors of polyADP-ribosylation to induce death of cancer cells. The Core will assess genome-wide and
LINE-1 repeat methylation. RNA-seq data will be analyzed for expression of ERVs and other repetitive
elements in tumors and sorted immune cells.

## Key facts

- **NIH application ID:** 10886776
- **Project number:** 5P50CA254897-04
- **Recipient organization:** CORIELL INSTITUTE FOR MEDICAL RESEARCH
- **Principal Investigator:** Jaroslav Jelinek
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $238,562
- **Award type:** 5
- **Project period:** 2021-08-16 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10886776

## Citation

> US National Institutes of Health, RePORTER application 10886776, Genomics Core (5P50CA254897-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10886776. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*